EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. by Tan, Yi-Hung Carol et al.
UC Office of the President
Recent Work
Title
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and 
malignant pleural mesothelioma.
Permalink
https://escholarship.org/uc/item/6m24w1w9
Journal
Oncogenesis, 8(9)
ISSN
2157-9024
Authors
Tan, Yi-Hung Carol
Srivastava, Saumya
Won, Brian M
et al.
Publication Date
2019-09-04
DOI
10.1038/s41389-019-0159-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Tan et al. Oncogenesis            (2019) 8:49 
https://doi.org/10.1038/s41389-019-0159-6 Oncogenesis
ART ICLE Open Ac ce s s
EPHA2 mutations with oncogenic characteristics in
squamous cell lung cancer and malignant pleural
mesothelioma
Yi-Hung Carol Tan1, Saumya Srivastava2, Brian M. Won1, Rajani Kanteti1, Qudsia Arif3, Aliya N. Husain3, Hubert Li4,
Wickii T. Vigneswaran5, Ka-Ming Pang2, Prakash Kulkarni2, Martin Sattler6,7, Nagarajan Vaidehi4, Isa Mambetsariev2,
Hedy L. Kindler1, Deric L. Wheeler8 and Ravi Salgia2
Abstract
Squamous cell carcinoma (SCC) and malignant pleural mesothelioma (MPM) are thoracic malignancies with very poor
prognosis and limited treatment options. It is an established fact that most of the solid tumors have overexpression of
EPHA2 receptor tyrosine kinase. EPHA2 is known to exhibit opposing roles towards cancer progression. It functions in
inhibiting cancer survival and migration via a ligand and tyrosine kinase dependent signaling (Y772). Whereas it is known
to promote tumor progression and cell migration through a ligand-independent signaling (S897). We analyzed the
expression profile and mutational status of the ephrin receptor A2 (EPHA2) in SCC and MPM cell lines and primary patient
specimens. The EPHA2 receptor was found to be either overexpressed, mutated or amplified in SCC and MPM. In
particular, the EPHA2 mutants A859D and T647M were interesting to explore, A859D Y772 dead mutant exhibited lower
levels of phosphorylation at Y772 compared to T647M mutant. Molecular Dynamics simulations studies suggested that
differential changes in conformation might form the structural basis for differences in the level of EPHA2 activation.
Consequently, A859D mutant cells exhibited increased proliferation as well as cell migration compared to controls and
T647M mutant. Kinomics analysis demonstrated that the STAT3 and PDGF pathways were upregulated whereas signaling
through CBL was suppressed. Considered together, the present work has uncovered the oncogenic characteristics of
EPHA2 mutations in SSC and MPM reinstating the dynamics of different roles of EPHA2 in cancer. This study also suggests
that a combination of doxazosin and other EPHA2 inhibitors directed to inhibit the pertinent signaling components may
be a novel therapeutic strategy for MPM and Non-small cell lung cancer patients who have either EPHA2 or CBL alterations.
Introduction
Squamous cell carcinoma (SCC) is the second most
common histology in non-small-cell lung carcinomas
(NSCLCs) accounting for 20–30% of all NSCLC cases and
more often than not, presents with advanced stage disease
at diagnosis.1 However, compared to advanced lung ade-
nocarcinoma, for which targeted therapies are now
available, especially if they present actionable mutations,
there are limited treatment options for advanced SCC,
both in first-line and relapsed/refractory settings. In the
last few years several new drugs that include necitumu-
mab (anti-EGFR monoclonal antibody) in combination
with standard chemotherapy, and immune-checkpoint
inhibitors such as nivolumab, pembrolizumab, or atezo-
lizumab have been approved for treating SCC.2 Although
the response has been encouraging, new and more effi-
cacious drugs are still needed.
Malignant pleural mesothelioma (MPM) is a neoplasm
that arises from the serosal surfaces of pleura, perito-
neum, and pericardium. It is a rare disease with
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approximately one in 100,000 people being diagnosed per
year in the US. This disease most often affects individuals
that have been exposed to asbestos; however, genetic
factors may also have a role. Median survival from the
time of diagnosis is ~9.2 months. Treatment options
include surgery and/or chemotherapy.3,4 Unfortunately,
only one chemotherapeutic agent (pemetrexed) has been
approved by the FDA for treatment of this disease.5,6
Thus, in order to make a significant impact on the therapy
and overall survival for patients with MPM, newer bio-
logical mechanisms need to be identified, and imple-
mented therapeutically.
The erythropoietin-producing hepatocellular carcinoma
(Eph) receptors that represent the largest family of
receptor tyrosine kinases (RTKs),7 are divided into EPHA
and EPHB classes based on structural homology and
ligand-binding affinity.8 A singular feature of the Eph-
ephrin system is that signals are transduced by both the
receptor (forward signaling) and the ligand (reverse sig-
naling) to form an important cell communication system
with critical and diverse roles in a variety of biological
processes during embryonic development.
EPHA2 is a 130 kDa protein consisting of 976 amino
acids. The EPHA2 gene is located on chromosome 1p and
contains 17 exons spanning 31 kilobases. The extracellular
region of the EPHA2 receptor consists of the ligand-binding
domain, a cysteine-rich domain and two fibronectin-III
domains (Fig. 1). The cytoplasmic region consists of a
tyrosine kinase (TK) domain and a sterile alpha motif
(SAM). The kinase domain and juxta membrane region
contain multiple tyrosine residues. The two key sites here
are the Y772, once activated is known to inhibit cancer cell
survival and migration and S897, which aids in cancer
progression.9–12 Phosphorylation of these tyrosine residues
creates docking sites for signaling proteins containing SH2/
SH3 domains such as Fyn, Src, Nck and Crk, RasGAP,
LMW-PTP, PI3-kinase and the adapter proteins Grb2,
Grb10, and SLAP. A number of these proteins regulate
depolymerization of the actin cytoskeleton13 while others
modulate cell adhesion.14 Several S/T/Y residues are
phosphorylated intracellularly with important functions in
vascular assembly, angiogenesis, and cell migration.15
Previously, it was shown that EPHA2 is expressed in
lung cancer and that it is also a prognosticator of the
disease.12 Furthermore, our previous studies on EPHB4 in
NSCLC had shown that when overexpressed, EPHA2
induced the resistance to EPHB4 inhibitors.16 In this
study, we investigated the expression, activation, and
genetic alterations related to EPHA2 in SCC and MPM as
well as the potential therapeutic role of modulating
EPHA2 in both diseases. Based on where the mutation
occurs, EPHA2 mutants behave differently since the
mutations differentially affect EPHA2 phosphorylation
and downstream signaling. We also observed inhibition
with doxazosin17 had an additive effect with cytotoxic
chemotherapies such as cisplatin.
Fig. 1 EPHA2 protein structure. EPHA2 receptor consists of the ligand-binding domain, a cysteine-rich domain, two fibronectin-III domains, a
tyrosine kinase (TK) domain, a sterile alpha motif (SAM), and a PDZ-binding motif. Novel mutations (yellow) and known SNPs were found in ligand-
binding domain and TK domain by us recently
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Results
EPHA2 alteration in SCC and MPM tissues and cell lines
First, we interrogated SCC and MPM tumor samples
and cell lines for genetic alterations in EPHA2. Genomic
DNA from 35 SCC, 39 MPM patient tumors, and six
MPM cell lines (H28, H513, H2052, H2373, H2461, and
H2596) was used for mutation and amplification ana-
lysis. Twenty-eight percent (11/39) of MPM patient
samples had EPHA2 mutations (Fig. 2) but none were
observed in SCC except for the mutant R876H.
Approximately 10% (4/39) of MPM patient samples and
33% (2/6) of MPM cell lines had EPHA2 gene amplifi-
cation (Fig. 3).
EPHA2 protein expression in MPM cell lines and in MPM
and SCC tumor tissues
Next, we evaluated EPHA2 protein expression in mul-
tiple MPM cell lines. Total cell lysates from six MPM cell
lines (H28, H513, H2052, H2373, H2461, and H2596) and
the normal mesothelial cell line Met-5A were used to
determine protein expression by immunoblotting. Com-
pared with Met-5A, the H28 and H2461 MPM cell lines
showed low expression of EPHA2 while the H513, H2052,
H2373, and H2596 MPM cell lines had high expression of
EPHA2. In all, EPHA2 was overexpressed in 66.7% (4/6)
of the MPM cell lines (Fig. 4a).
EPHA2 expression was analyzed in tumor specimens by
immunohistochemistry (IHC) utilizing a tissue microarray
(TMA) (Fig. 4b). The overall IHC scores for 65 MPM tumor
samples and nine normal mesothelium samples of EPHA2
were 2.74 and 2.06, respectively, demonstrating that EPHA2
is overexpressed in MPM. We further determined the
expression of phospho-EPHA2 and the ligand ephrin A1
(EFNA1) in the same TMA. The results showed that, in
comparison with normal tissue, phospho-EPHA2 expres-
sion was low while EFNA1 was overexpressed (Fig. 4c). The
overall IHC scores for the 48 SCC tumor samples and 44
adjacent normal samples for EPHA2 were 1.74 and 0.5,
respectively (Fig. 4d). These results showed that, in
Fig. 2 EPHA2 gene sequencing chromatograms. Representative sequencing chromatograms of the mutation region in normal (N) and tumor (T)
samples. Boxes indicate the heterozygous mutation in the tumor sample. a Novel mutation (R159G and R876C) and known single-nucleotide
polymorphism (SNPs) (P350T, G391R, M631T, R876H, and R890Q) were detected in SSC tumor tissue. b Novel mutation (T140I, D184Y, T647M, and
A859D) and known SNPs (R195C, D232G, T647T, and R876H) were detected in MPM tumor tissue. R159G, T140I, D184Y, R195C, and D232G were found
in exon 3, P350T was found in exon 5, T647T/M were found in exon 10, M631T was found in exon 11, A859D/A and R876H/R were found in exon 15.,
and R876C, R876H, and R890Q were found in exon 16
Fig. 3 EPHA2 gene amplification in SSC and MPM samples. Thirty
five SCC, 39 MPM tumor samples, and six cell lines have been used to
determine EPHA2 gene amplification. Fold change relative to
reference gene LINE-1
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comparison with normal tissue, phospho-EPHA2 expres-
sion is low while EFNA1 is high in MPM tumor samples.
Effect of EPHA2 expression on cell proliferation and
migration
Having established that EPHA2 is overexpressed, we next
determined the effect of overexpression on cellular pro-
liferation and migration. As shown in Fig. 5a, in HEK293
EPHA2 isogenic cells, cell proliferation was increased in
comparison with HEK239 cells that had low EPHA2
expression. Furthermore, the cells with EPHA2 A859D and
T647M mutations significantly increased proliferation
compared to cells with wild-type (WT) EPHA2 (Fig. 5a).
EPHA2 A859D mutant cells performed better than T647M
cells. A wound healing assay was used to determine cell
migration of HEK293 EPHA2 isogenic cells expressing WT
and mutant (Mt) EPHA2. Wound healing was monitored at
2 and 5 h and in both cases, cell migration was significantly
increased in EPHA2 A859D mutant in comparison with
T647M mutant and HEK239 cells (Fig. 5b).
Inhibition of cell proliferation in EPHA2 isogenic cell lines
of SCC and MPM with chemo drugs and small molecules
To discern the effect of chemotherapy and pharmaco-
logical inhibition of EPHA2, BEAS2B EPHA2 isogenic
cells with WT and Mt receptor (G391R) were treated with
the chemo drugs taxol and cisplatin and small molecule
inhibitors including the MET inhibitor SU11274 and the
mTOR inhibitor, Rapamycin. EPHA2 Mt cells showed
higher sensitivity to inhibition with small molecules than
traditional chemo drugs compared to EPHA2 WT cells
(Fig. 6a–d). HEK293 EPHA2 isogenic cell lines and MPM
cell lines were also used to determine the effectiveness of
cisplatin. MPM cell lines (H513, H2052, and H2596) that
overexpressed EPHA2 showed sensitivity to cisplatin
inhibition (Fig. 7a). In contrast, MPM cell lines with low
EPHA2 expression (H28 and H2461) showed resistance to
cisplatin treatment (Fig. 7a). In addition, HEK293 EPHA2
isogenic cells showed inhibition with small molecule
inhibitor, doxazosin. In contrast, treating HEK293
EPHA2-A859D Mt cells with doxazosin showed sig-
nificant resistance to doxazosin (Fig. 7b). This resistance
was not observed in T647M mutant, EPHA2 WT, or
empty vector control.
EPHA2 mutations affect multiple phosphorylation of RTKs
To elucidate the mechanism, we next determined the
phospho-kinome of EPHA2 A859D and T647M mutants
with or without doxazosin treatment. The analysis
showed that tyrosine kinase activity responsible for
Fig. 4 EPHA2 expression in MPM cell lines and in MPM and SCC tumor tissues. a Lysates of six MPM cell lines and the Met-5A, a mesothelial
control cell line, were immunoblotted with EPHA2 antibody. b Immunohistochemistry representative pictures of 65 MPM tumor and nine normal
mesothelium samples were used in MPM TMA. c Protein expression quantity of 65 MPM tumor and nine normal mesothelium samples were used in
MPM TMA. d Protein expression quantity of 48 NSCLC SQ and 24 adjacent normal samples were used in SSC TMA. H&E, EPHA2, phospho-(p-)EPHA2,
and ephrin A1 were stained and scored. N: normal, T: Tumor
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phosphorylating most peptides of EPHA2 Mts was
downregulated compared to empty vector control. After
treatment with doxazosin, wild-type EPHA2 group and
T647 mutant showed significant upregulation (p < 0.05)
than EPHA2 A859D Mts group. A volcano plot showing
the changes of each group compared to empty vector
group is presented in Supplementary Fig. 1.
To understand the network of affected peptides, a signal
transduction network with significantly down- and upre-
gulated peptides was predicted and created by Ingenuity
Fig. 5 Cell viability and migration of HEK293 EPHA2 isogenic cells. a Cell viability was measured every 24 h over 72 h. b Cell migration was
measured by wound healing assay at 0, 2, and 5 h
Fig. 6 Cell cytotoxicity of SCC EPHA2 isogenic cells with chemo drugs and small molecular inhibition. BEAS2B EPHA2 isogenic cells were used
to treat a Taxol, b cisplatin, c SU11274, and d rapamycin. Mutation G391R cells showed resistant to cisplatin inhibition but sensitive to MET inhibitor
SU11274 and mTOR inhibitor Rapamycin. EV: empty vector
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Pathway Analysis (IPA®) software tool (Qiagen, Redwood
City, CA) (Supplementary Fig. 2a). The analysis revealed
that Tec kinase signaling, STAT3 pathway, axonal gui-
dance signaling, T cell receptor signaling, and PDGF
signaling were the top canonical pathways (p < 0.001)
involved in all the groups with or without doxazosin
treatment. In addition, cancer, post-translational mod-
ification, and cell-to-cell signaling and interaction were
the networks, which had the most affected peptides
involved (Supplementary Table 1 and Fig. 2b).
Molecular dynamics simulations
The residue Y772 in the kinase domain of EPHA2 gets
auto-phosphorylated upon ligand-binding leading to the
catalytic kinase activity of EPHA2. Our phosphorylation
assays (Fig. 8) have shown that the mutant A859D shows
low level of phosphorylation and the mutant T647M shows
medium level of phosphorylation compared to the wild-type
EPHA2. To rationalize this experimental finding, we per-
formed molecular dynamics (MD) simulations on the
kinase domain structure of EPHA2 starting from the crystal
structure of the auto-inhibited conformation of EPHA2, in
explicit water as described in the Methods section. We also
performed MD simulations of the two mutations A859D
and T647M under the same conditions as the wild type.
Our hypotheses are two-fold: (i) the residue Y772 in
EPHA2 should get close (within 4 Å) to the γ-PO4 group of
ATP to facilitate the phosphoryl transfer to Y772. (ii) The
mutations A859D and T647M could affect the dynamic
proximity of the γ-PO4 of ATP to Y772 thereby reducing
the phosphorylation of Y772. Additionally, the shape of the
ATP binding site could be affected by the mutations thereby
affecting the binding affinity of ATP to EPHA2. K702 is a
residue that binds close to the γ-PO4 of ATP and hence we
used this residue to locate the ATP binding site. Figure 8a
shows that the distance between Y772 and K702 is 23.7 Å in
the crystal structure of the auto-inhibited state of EPHA2.
Figure 8b shows the minimum distance between Y772 and
K702 achieved during the MD simulations. This shows that
the dynamics of the wild-type EPHA2 brings the Y772 close
enough to ATP to get phosphorylated. Figure 8c shows the
distribution in the distance between Y772 and K702 during
the MD simulations of the wild type and the two mutants. It
is seen that the wild-type and T647M mutant show closer
distances between Y772 and K702, the mutant A859D does
not get Y772 close to K702 during the dynamics of the
kinase domain. This could impair the phosphorylation of
Y772 in the A859D mutant compared to the wild-type. The
distance distribution in T647M is broader than that of the
wild-type. We have also calculated the volume of the
binding cavity of ATP as shown in Fig. 8d, and the dis-
tribution of the volume in (Å3) of the ATP binding site for
the wild-type and the two mutants calculated from the
snapshots of the MD simulations is shown in Fig. 8e. The
distribution of the volume of the ATP binding site is the
broadest for A859D, followed by T647M and then the wild-
type. This shows that the ATP binding site is very flexible in
A859D mutant that could possibly lead to faster off-rate of
ATP and thus reducing the binding affinity of ATP and
therefore it’s potential to phosphorylate Y772 in the mutant
A859D EPHA2. These differential changes in conformation
captured by the MD simulations provide a structural basis
for the differences in the level of Y772 phosphorylation and
explains the trend observed in the phenotypic changes.
Discussion
In this study, employing a variety of biological, bio-
chemical, and computational tools, we have uncovered the
oncogenic vs tumor suppressor characteristics of EPHA2
and its mutations in SSC and MPM. In addition to identi-
fying novel mutations, the EPHA2 gene is amplified or the
protein is overexpressed in these two diseases. It is well
Fig. 7 Cell cytotoxicity of HEK293 EPHA2 isogenic cells. a MPM cell lines H28, H513, H2052, H2373, H2461, and H2596 were treated with cisplatin
with 1, 5, and 10 μM for 48 h. b HEK293 EPHA2 isogenic cells treatment with doxazosin for 48 h
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established that, in cancer cells, EPHA2 protein is typically
not phosphorylated due to the overexpression of LMW-
PTP phosphatase in these cells.18 Thus, the decreased levels
of p-EPHA2 and enhanced levels of total EPHA2 appear to
result from enhanced protein stability.19 Nonetheless the
phosphorylation status of EPHA2 leads to differential acti-
vation of signaling pathways resulting in different outcomes
in terms of cancer progression. The tumorigenic signature
of EPHA2 is defined by ligand-independent high levels of
S897 phosphorylation and ligand- and kinase-dependent
low levels of Y772 phosphorylation. Therefore, among the
several novel mutations identified in this study, the muta-
tions in the tyrosine kinase domain in particular were
assayed. Mutations A859D and T647M displayed con-
trasting phenotypes. A859D, the Y772 dead mutant, showed
increased cell proliferation and migration of MPM cells in
comparison to T647M mutant and control cells. Further-
more, we also observed a stimulation of growth with low
dose of cisplatin and SU11274 treatment (Fig. 6b, c). Also,
EPHA2 mutation A859D, conferred resistance to targeted
therapy as well as cisplatin chemotherapy. The Y772
phosphorylation is much reduced in A859D mutant than in
T647M mutant. To understand the difference seen in the
phenotypes of these two mutants, we carried out compu-
tational MD simulation studies to model the dynamics of
the kinase domain and probe the intramolecular interac-
tions that lead to phosphorylation of Y772. Our analysis of
the MD simulation trajectories showed that the A859D
mutant impairs the phosphorylation by reducing the flex-
ibility of the loop containing Y772 and therefore getting
closer to the ATP for direct phosphoryl transfer. Addi-
tionally, the EPHA2 A859D mutant shows increased
volume of the ATP binding site compared to the wild-type
EPHA2, that leads to faster off-rate of ATP and lowering
the affinity of ATP to this mutant. These two factors
together provide atomic-level insights into the impairment
of phosphorylation of Y772 in the mutant A859D. This
explains why we see decreased phosphorylation at Y772 in
A859D cells. The absence of the inhibiting phosphorylation
in A859D mutant, leads to increased cell proliferation and
migration and reduced sensitivity to chemotherapeutic or
small molecule drug treatments Fig. 9.
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Fig. 8 Molecular dynamics simulations. a The crystal structure of EphA2 in the auto-inhibited conformation. The distance between Y772 and
K702 shown by dotted line is 20.3 Å, b The EphA2 conformation after MD simulations showing the minimum distance between Y772 and K702 which
is 3.4 Å, c The distribution of the distance between Y772 and K702 in the wild type and mutants A859D and T647M, d The surface showing the ATP
binding site in EphA2, and e The distribution of the volume in (Å3) of the ATP-binding site for the wild type and the two mutants calculated from the
snapshots of the MD simulations
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We also found that CBL was downregulated in H2373
EPHA2 isogenic cells (low EPHA2 expression) and upre-
gulated after treatment with doxazosin. CBL is an E3
ubiquitin ligase and an adaptor molecule that plays an
important role in NSCLC.20 CBL is often observed to have
low expression in cancer cells especially in NSCLC.
Interestingly, our study showed that low expression of
CBL results in MET overexpression and increased cell
proliferation and migration suggesting that patients with
low CBL expression or mutation may benefit from MET
inhibitor, e.g., SU11274 due to increased expression of
MET.21 Lastly, in light of the fact that doxazosin treat-
ment results in upregulation of CBL, a combination of
doxazosin and other EPHA2 inhibitors may be a novel
therapeutic strategy for MPM and NSCLC patients who
have either EPHA2 or CBL alterations.
Materials and methods
Source of sample materials
The research on human subjects in this paper utilized
tissue samples from patients with cytologically or histo-
logically documented SCC and MPM. Samples utilized
were archival samples already banked by the University of
Chicago Human Tissue Resource Center, Clinical
Research Center, and Pathology Department. These tis-
sues were obtained with subject consent (under IRB pro-
tocols #9571 and #13473 A) or under consent-waived
protocols for deceased or de-identified patients. For all
samples, clinical information (date of diagnosis, survival,
asbestos exposure, etc.) was obtained from patient medical
records and/or the Thoracic Oncology Research Program
(TORP) database at the University of Chicago, developed
by the Salgia laboratory that is freely available on the
iBridge Network website (http://www.ibridgenetwork.org/
uctech/salgia-thoracic-oncology-access-template).22,23
EPHA2 expression
Expression of EPHA2 was assessed in tumor tissues
obtained from patients with various histologies of SCC
and MPM. We utilized tumor tissue microarrays (TMAs)
and performed immunohistochemistry (IHC) with anti-
bodies against EPHA2 and phospho-EPHA2 as well as the
EPHA2 ligands ephrin A1, EPHA3, and EPHA3 ligand
ephrin A5. EPHA3 and its ligand were used as a potential
alternative Eph receptor. SSC and MPM TMAs were
constructed from archival tumor tissues obtained from
untreated patients, diagnosed in 2003 or later and 30
normal controls. For each patient/control, two replicate
tissue samples were evaluated. Immunostained TMAs
were blindly scored by pathologists utilizing bright-field
microscopy. IHC score is calculated by taking into
account the strength of staining intensity combined with
the extent of staining area to determine a final score (0,
negative; 1+ , weak; 2+ , moderate; and 3+ , strong
expression). MPM cell lines: H28, H513, H2052, H2373,
H2461, and H2596 were analyzed for protein expression
by immunobloting as described previously.16 Met-5A, the
normal mesothelial cell line, was used as control.
Quantitative real-time PCR
Quantitative real-time PCR using DNA samples
obtained from tumors of patients with SCC and MPM was
performed to determine the gene amplification. The PCR
primers used are listed in Supplementary Table 2. Ste-
pOne real-time PCR system and Power SYBR Green PCR
Master Mix (Applied Biosystems) were used to perform
the experiment. Relative gene copy number was calcu-
lated from the real-time PCR efficiencies, which were
determined for each individual run, and the crossing point
deviations of the target and reference genes in a test
sample versus a control. Long interspersed element-1
(LINE-1) served as reference gene, which is a repetitive
element for which copy numbers per diploid genome are
similar in healthy or malignant human cells.24 Reactions
were done in triplicate under standard thermocycling
conditions (one cycle of 95 °C for 10 min, followed by 40
cycles of 95 °C for 30 s and 58 °C for 1 min), and the mean
threshold cycle number was used.
Gene mutation analysis
Exons 1–17 of EPHA2 gene were individually ampli-
fied by PCR. The primers are listed in Supplementary
Table 3. PCR conditions were as follows: 1 cycle of 95 °C
for 5 min; 35 cycles of 94 °C for 30 s, 58 °C for 30 s and
72 °C for 2 min; and one cycle of 72 °C for 10 min. PCR
products were treated with ExoSAP-IT (USB Corpora-
tion, Cleveland, OH, USA) and sequenced by Big-Dye
Terminator Chemistry (Applied Biosystems, Foster City
CA). Sequencing was performed on the forward coding
strand with confirmation of EPHA2 alterations
Fig. 9 The EPHA2 mechanistic model. The model depicts how in
the A859D mutant loss of Y772 phosphorylation leads to enhanced
tumorigenesis in comparison to T647M mutant
Tan et al. Oncogenesis            (2019) 8:49 Page 8 of 11
Oncogenesis
performed by sequencing the reverse strand as well.
Chromatograms were analyzed for mutations using
Mutation Surveyor v2.61 software (Softgenetics, State
College, PA).
Plasmid constructs and site-directed mutagenesis
The wild-type EPHA2 construct (pCMV6-AC-
GFP–EPHA2) was purchased from OriGene (Rockville,
MD). Using this parental plasmid, the TKB domain
mutation T647M and A859D were created using the
following primers: (Forward) 5’-GTGGCCATCAAGATG
CTGAAAGCCGG-3’/ (Reverse) 5’-GCCGGCTTTCAGC
ATCTTGATGGCCAC-3’ and (Forward) 5’-CAGGAGCG
TGACCGCCGCCCC-3’/ (Reverse) 5’-GGGGCGGCGGG
TCACGCTCCTG-3’, respectively, along with their com-
plementary primers using the QuickChange Site-Directed
Mutagenesis XL kit (Stratagene, La Jolla, CA) following
the manufacturer’s instructions. Point mutations were
confirmed by standard DNA sequencing of both strands.
Transfection of EPHA2 constructs
HEK293 and MPM cell lines, which expressed low
EPHA2, were transfected using the Fugene HD (Roche,
Nutley, NJ) reagent according to the manufacturer’s
instructions. We utilized HEK293 cells as a high-
throughput model for determining the efficacy of the
plasmid and transfection efficiency. Eight microgram of
plasmid DNA, containing either no insert (empty vector),
wild-type (WT) EPHA2, A859D EPHA2, or T647M
EPHA2 was used for transfection in a six-well culture
plate. Transfection efficiency was detected by observing
GFP expression under microscope after 24 h transfection.
EPHA2 knockdown
EPHA2 knockdown was performed by transfecting cells
with EPHA2 shRNA (OriGene, Rockville, MD) as per
manufacturer’s instructions. Briefly, 1 × 105 cells/well of
H513 or MPM cell lines with high EPHA2 expression
were seeded in six-well plates and transfected the fol-
lowing day with EPHA2 shRNA constructs. To generate
stable EPHA2 knockdown cell lines, cells were selected for
1–2 weeks with 1 μg/ml puromycin. EPHA2 expression
levels were determined in whole-cell lysates by immuno-
blotting using anti-EPHA2 antibody (Santa Cruz Bio-
technologies, Santa Cruz, CA).
Cell viability assay and drug treatment
EPHA2 isogenic cells were transfected with EPHA2 WT
and mutants (Mts) as described above. forty-eight hour
after transfection, cells were harvested and re-seeded at
5 × 104 cells/well in a 24-well culture plate. Cell viability
was monitored 24, 48, and 72 h and determined using
Calcein-AM exclusion. After seeding the cells for 24 h,
cells were treated with cisplatin, taxol, rapamycin,
SU11274, or doxazosin and monitored 24, 48, and 72 h
and determined using Calcein-AM exclusion.
Wound healing assay
EPHA2 isogenic cells were transfected with EPHA2 WT
and Mts as described above. Cells were seeded in six-well
plates and cultured for 48 h until 100% confluent. After
resting the cells for 12 h, a straight scratch was made
across the cell layer using a 1 ml pipette tip. The cells were
then gently washed with 1X PBS to remove cellular debris
and the media was replaced. Photographs of the wound
region were taken 0, 2, and 5 h had passed. The images
were analyzed using the TScratch software (Computa-
tional Science and Engineering Laboratory, ETH Zurich,
Switzerland).
Immunoblotting
Cells were collected at 48 h after transfection and
washed twice in 1X PBS, then lysed with ice-cold lysis
buffer (0.5M Tris-HCl with pH 7.4, 1.5M NaCl, 2.5%
deoxycholic acid, 10 mM EDTA, 10% NP-40, 0.5 mM
DTT, 1 mM phenylmethylsulfonyl fluoride, 5 µg/mL leu-
peptin, and 10 µg/mL aprotinin) for 5 min. The lysate was
centrifuged at 13,000 rpm for 20min at 4 °C, and protein
content of the supernatant was measured. Total cell
lysates (50 µg/well) were separated by SDS-PAGE elec-
trophoresis and the gels transferred onto nitrocellulose
membranes (Whatman, Piscataway, NJ). Membranes were
blocked with 5% non-fat dry milk in PBST (1X PBS, 0.1%
Tween-20) for 1 h at room temperature and incubated
with the appropriate primary antibody at 4 °C overnight.
Membranes were then washed three times with PBST and
probed with the appropriate HRP-conjugated secondary
antibodies for 1 h at room temperature. The membranes
were again washed three times in PBST and bands were
visualized using western blot chemiluminescence reagent
(BioRad, Valencia, CA) on a Chemidoc Gel documenta-
tion system (BioRad). The following antibodies specific for
EPHA2, phospho (p)-EPHA2 (S897), p-EGFR (Y1125), p-
EPHA4, p-EPHA7 (Y60), and p-STAT1 (Y701) were used.
PamGene technology and analysis
The kinase activity of H2373 EPHA2 isogenic cells with
and without doxazosin was monitored using PamChip®
Tyrosine Kinase Array. Briefly, cells were treated with
doxazosin, harvested, and lysed in Mammalian Extraction
Buffer (M-PER, Pierce) containing phosphatase and pro-
tease inhibitors (HALT, Pierce). Following lysis, 5 μl of the
lysis solution was pipetted into a reaction mixture com-
posed of 1X ABL buffer (New England Biolabs), 0.1%
Bovine Serum Albumin, 100 μM ATP, 20 μg/ml phos-
photyrosine antibody in a total volume of 40 μl. PamChip
arrays were blocked with 0.2% BSA prior to loading the
samples. After loading the reaction mixtures onto the
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PamChip arrays real-time data for the kinase activity were
obtained by measuring fluorescence of the bound anti-
phosphotyrosine antibody after each of the five cycles.
Image quantification and data processing were conducted
with dedicated PamGene software Evolve and BioNavi-
gator (PamGene). The peptides that were significantly
differentially affected peptides and signaling pathways
were analyzed using Ingenuity IPA (Redwood City, CA).
Computational methods
Modeling of the EPHA2 kinase domain
The three-dimensional structures of two different con-
formations of the EPHA2 kinase domain were taken from
the protein data bank (PDB) (http://www.rcsb.org). The
PDB codes for these two structures are: 1MQB and
5EK7.25 These two structures both represent the “inac-
tive” conformations of the kinase domain. The “inactive”
conformation sequesters the residue Y772 (the phos-
phorylated residue) away from the ATP binding site. This
renders the kinase inactive. The two crystal structures
were selected because together both these structures
compensated for the missing activation loop structures in
each other. The wild-type sequence of the kinase domain
of EPHA2 was obtained from UniProt database and the
missing residues numbered 586–605, 634–638, and
887–893 were modeled with MODELLER using the two
listed structures as templates. A total of 50 homology
models for the missing loops were generated and the
models were evaluated by DOPE score and favorable
number of contacts formed between the residues along
the C-terminus that was added and the main body of the
protein. Mutant structures were then generated using the
Schrodinger Maestro program from Schrodinger Inc. to
create each SNP.26 The side chain conformations of the
mutation residue and the neighboring amino acids within
5 Å were optimized using Prime module (also from
Schrodinger Inc.).27 The side chain optimized model was
then minimized in energy.
Molecular Dynamics (MD) Simulation setup
MD Simulations were run using GROMACS version
5.0.5. The GROMOS96 53a6 force field was selected and
sufficient Cl- ions were added to neutralize each sys-
tem.28–32 Each model was solvated in a dodecahedron
using SPC/E water molecules with 10 Å to the boundary
edges. Each system was then minimized for a maximum of
500 steps by the steepest decent algorithm until the
maximum force was below 1000 kJ/mol/nm. NVT equi-
libration was carried out on each minimized structure for
500 picoseconds to 310 K.33 NPT equilibration was then
carried out for 500 picoseconds using the Parrinello-
Rahman barostat to equilibrate the system at 1
atmosphere-pressure.34 One replicate used the initial
velocities generated during equilibration and two other
replicates were initiated using random velocities. The
three replicates were run for a total of 350 nanoseconds
each for a collective simulation time of 1.05μs.
Computational analysis
Trajectories were concatenated processed using
VMD.35 Distances were calculated in Å, between the NZ
atom of K702 and the OH atom of Y772. Individual
representations of EPHA2 were visualized using
PyMOL.36 The volume of the catalytic site was calculated
by selecting one frame every 200 picosecond POVME
2.0.37,38 The script was modified to calculate the volume
at the centroid of the CA atoms of A644, Q656, D659,
A699, and G776. The graphs of distance and volume were
created using Matplotlib, structural representations were
generated using PyMOL, and binding volume repre-
sentations were generated using VMD.36,39
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